Santos David A 4

What Happened
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals (RIGL), was granted 19,430 restricted stock units (RSUs) on 2026-02-17. The RSUs were reported as acquired at $0.00 (award/grant), meaning no cash was paid; the shares will be delivered upon vesting.

Key Details

• Transaction date: 2026-02-17; transaction type: Award/Grant (code A); 19,430 RSUs @ $0.00.
• Vesting: RSUs vest quarterly over three years; first quarterly vesting occurs on March 31, 2026 (see footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing date: 2026-02-19 for a 2026-02-17 grant — appears to be filed within the usual Form 4 timing requirements (no late filing indicated).
• Footnote F1: Shares will be acquired upon vesting of the RSU award; they are not issued immediately.

Context
RSUs are a common form of executive compensation intended to align management with shareholders; they are not an open-market purchase or sale and do not by themselves signal a buy/sell view. Because these units vest over time, their economic value to the executive depends on future vesting dates and Rigel’s stock price at those times.